Search This Blog

Thursday, January 30, 2020

ResMed EPS beats by $0.18, beats on revenue

ResMed (NYSE:RMD): Q2 Non-GAAP EPS of $1.21 beats by $0.18; GAAP EPS of $1.10 beats by $0.17.
Revenue of $736.2M (+13.1% Y/Y) beats by $6.4M.
Press Release
https://seekingalpha.com/news/3536593-resmed-eps-beats-0_18-beats-on-revenue
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)